Search filters
Filters
Clear All

Phase

  • 2
  • 9
  • 10
  • 3
  • 3
  • 28
  • 16
  • 28
  • 28

Found 28 Non-Small Cell Lung Cancer trials

A listing of Non-Small Cell Lung Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

UPCC 10518: An Open Label Single Arm Phase 1b/2 Study to Evaluate the Safety and Efficacy of Grapiprant (ARY-007) in Combination with Pembrolizumab in Patients with Advanced or Metastatic Post PD 1/L1 Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma

99 years or below
All genders
Phase 2
The primary purpose of this study is to gain information about the safety and activity of grapiprant when taken with pembrolizumab in patients who have actively growing or spreading type of advanced stage lung cancer called non-small cell lung cancer (NSCLC).
Learn More
S1900B A Phase II Study of LOXO-292 in Patients with RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)

S1900B A Phase II Study of LOXO-292 in Patients with RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)

18 years - 99 years
All genders
Phase 2
This phase II LUNG-MAP treatment trial studies how well selpercatinib works in treating patients with RET fusion-positive non-small cell lung cancer that is stage IV or has come back (recurrent). Selpercatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth
Learn More
UPCC 15518 / ANAM-17-21: A Phase 3 Randomized Double-Blind Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

UPCC 15518 / ANAM-17-21: A Phase 3 Randomized Double-Blind Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

18 years - 99 years
All genders
Phase 3
The main purpose of this study is to learn more about how well the experimental drug, anamorelin hydrochloride (HCl), works to prevent weight loss and anorexia in patients with advanced Non-Small Cell Lung Cancer.
Learn More
Functional Lung Avoidance Radiation Therapy Using Hyperpolarized Xenon-129 MRI

Functional Lung Avoidance Radiation Therapy Using Hyperpolarized Xenon-129 MRI

18 years - 99 years
All genders
Phase 1
The primary outcomes will be to establish the safety and feasibility of inhaled imaging in patients with NSCLCand to develop a robust RT planning protocol incorporating both standard of care metrics and those derived from inhaled imaging
Learn More
UPCC 01617: A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination with Nivolumab in Subjects with Non-small Cell Lung Cancer and Subjects with Metastatic Melanoma

UPCC 01617: A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination with Nivolumab in Subjects with Non-small Cell Lung Cancer and Subjects with Metastatic Melanoma

99 years or below
All genders
Phase 2
Request for collaborative review: WIRB serving as IRB of record.
Learn More
A pilot study to determine the feasibility of using plasma to detect mutations in patients with Stage II-III NSCLC

A pilot study to determine the feasibility of using plasma to detect mutations in patients with Stage II-III NSCLC

18 years - 99 years
All genders
This study will increase our ability to detect mutations in Stage II-III Non Small Cell Lung Cancer patients.
Learn More
An Open-Label Safety and Tolerability Phase 1b Trial of CAN04 A Fully Humanized Anti-IL1RAP Monoclonal Antibody in Combination with Pembrolizumab in Subjects with Solid Tumors Progressing on PD-1/PD-L1 Inhibitor-Containing Regimens

An Open-Label Safety and Tolerability Phase 1b Trial of CAN04 A Fully Humanized Anti-IL1RAP Monoclonal Antibody in Combination with Pembrolizumab in Subjects with Solid Tumors Progressing on PD-1/PD-L1 Inhibitor-Containing Regimens

99 years or below
All genders
Phase 1
This study will consider the safety and effectiveness of a study drug, CAN04, in combination with pembrolizumab, in the treatment of incurable or metastatic non-small-cell lung cancer, head and neck squamous cell carcinoma, urothelial cancer, or malignant melanoma. The study aims to establish a recommended dose of CAN04 in combination …
Learn More
UPCC 05519: Single-Arm Study Of Carboplatin Weekly Taxane And Ramucirumab In Advanced NSCLC After Progressive Disease On Maintenance Pemetrexed And/Or Pembrolizumab

UPCC 05519: Single-Arm Study Of Carboplatin Weekly Taxane And Ramucirumab In Advanced NSCLC After Progressive Disease On Maintenance Pemetrexed And/Or Pembrolizumab

18 years - 100 years
All genders
Phase 2
The purpose of this study is to determine if the combination of the three anti-cancer drugs carboplatin, paclitaxel, and ramucirumab is helpful in shrinking tumors or delaying tumor growth in participants with non-small cell lung cancer. This study will also assess whether it is safe to combine these drugs.Participants for …
Learn More
21 - 28 of 28